EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nuclear SOX9 Expression and Short-Term Survival Outcomes in Early-Stage Luminal Breast Cancer: An Immunohistochemical and Retrospective Cohort Analysis

Ebru Karci iD, Sabin Goktas Aydin iD, Osman Erinc iD, Taskin Erkin Uresin, Sevinc Dagistanli, Nilay Bakoglu Malinowski iD, Ahmet Aydın iD, Onur Tanrikulu

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27188337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ebru Karci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Istanbul Atlas University, 34408 Istanbul, Turkey. Hauptthemen laut MEDLINE: SOX9 Transcription Factor, Breast Neoplasms, Cell Nucleus. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SOX9 is a transcription factor linked to cellular plasticity and aggressive behavior in breast cancer. We investigated whether nuclear SOX9 expression correlates with short-term (5-year) survival outcomes in luminal breast cancer. In a retrospective cohort of 60 patients with estrogen receptor-positive invasive breast carcinoma, nuclear SOX9 expression was evaluated via immunohistochemical H-scores (0–300). Survival was analyzed continuously, by median-split dichotomy, and using a 1% nuclear-staining threshold via Kaplan–Meier and Cox regression models. Most tumors were luminal B (73.3%), and 45% were node-positive. Nuclear SOX9 was detected in 51.7% of cases (median positive H-score: 30). Over follow-up, 13 disease-free survival (DFS) and 12 overall survival (OS) events occurred. Continuous H-score did not correlate with clinicopathological variables, DFS (p = 0.576), or OS (p = 0.613). A median-split showed higher 5-year DFS for high-expression tumors (89.7% vs. 74.2%, p = 0.048), but this borderline protective trend was unconfirmed by Cox regression (p = 0.063) or the 1% threshold; ROC analysis showed no discrimination (AUC: 0.34–0.36). Standalone nuclear SOX9 expression has no significant impact on short-term (5-year) prognosis in early-stage luminal breast cancer; extended follow-up is warranted to assess potential late recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SOX9 Transcription FactorBreast NeoplasmsCell NucleusHumansFemaleRetrospective StudiesImmunohistochemistryMiddle AgedAgedBiomarkers, TumorAdultDisease-Free SurvivalNeoplasm StagingPrognosis

Stichwörter der Autor:innen

H-scoreSOX9cellular plasticitydisease-free survivalimmunohistochemistryluminal breast canceroverall survivalprognostic biomarker

Substanzen

SOX9 Transcription FactorSOX9 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine, Istanbul Atlas University, 34408 Istanbul, Turkey.
  • Department of Medical Oncology, South Tees Hospitals NHS Foundation Trust, Middlesbrough TS4 3BW, UK.
  • Department of Internal Medicine, Kanuni Sultan Suleyman Training and Research Hospital, 34303 Istanbul, Turkey.
  • Department of Pathology, Kanuni Sultan Suleyman Training and Research Hospital, 34303 Istanbul, Turkey.
  • Department of General Surgery, Kanuni Sultan Suleyman Training and Research Hospital, 34303 Istanbul, Turkey.
  • Department of Pathology, Faculty of Medicine, İstanbul Medipol University, 34214 Istanbul, Turkey.

ORCID-Profile: Ebru Karci, Sabin Goktas Aydin, Osman Erinc, Nilay Bakoglu Malinowski, Ahmet Aydın

Zitieren

APA

Karci, E., Goktas Aydin, S., Erinc, O., Uresin, T. E., Dagistanli, S., Bakoglu Malinowski, N., Aydın, A., & Tanrikulu, O. (2026). Nuclear SOX9 Expression and Short-Term Survival Outcomes in Early-Stage Luminal Breast Cancer: An Immunohistochemical and Retrospective Cohort Analysis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188337

Vancouver

Karci E, Goktas Aydin S, Erinc O, Uresin TE, Dagistanli S, Bakoglu Malinowski N, et al. Nuclear SOX9 Expression and Short-Term Survival Outcomes in Early-Stage Luminal Breast Cancer: An Immunohistochemical and Retrospective Cohort Analysis. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188337

BibTeX
@article{Karci2026,
  author = {Karci, Ebru and Goktas Aydin, Sabin and Erinc, Osman and Uresin, Taskin Erkin and Dagistanli, Sevinc and Bakoglu Malinowski, Nilay and Aydın, Ahmet and Tanrikulu, Onur},
  title = {Nuclear SOX9 Expression and Short-Term Survival Outcomes in Early-Stage Luminal Breast Cancer: An Immunohistochemical and Retrospective Cohort Analysis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27188337}
}
Kostenlos starten →